Deal-Ticker: MoonLake Immunotherapeutics AG closes Series A financing round
MoonLake Immunotherapeutics AG, a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases, has closed a Series A financing lead by BVF Partners LP. Other investors include Merck KGaA, Darmstadt, Germany.
MoonLake Immunotherapeutics AG has been established by an international team of immunology specialists with decades of experience in immunology, comprising Arnout Ploos van Amstel and Prof. Dr. Kristian Reich, to create next-level therapies for inflammatory skin and joint diseases. MoonLake in-licensed the remarkable Tri-specific Nanobody® Sonelokimab with game-changing potential in the treatment of inflammatory diseases from Merck KGaA and Ablynx. MoonLake will accelerate the clinical development of Sonelokimab for the treatment of inflammatory diseases in dermatology and rheumatology.
Kellerhals Carrard acted as lead legal advisor to MoonLake Immunotherapeutics AG on this transaction. The team of Kellerhals Carrard comprised Nicolas Mosimann (Lead), Marco Sibold, Larissa Simeon and Sophie Holdt (all Corporate/VC) and Melanie Huber (Employment Law).